CareLit · DOI-Nachweis · Pneumologie
Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: NeoIntercal
DOI 10.1055/s-0036-1572237
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Griesinger, M Sebastian, M Serke, C Grohé, L Hillejan, B Passlick, N Reinmuth, U Graeven, S Radke, A Karatas, M Tiemann, T Overbeck
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: EGFR TKI treatment is standard of care in patients with metastasized NSCLC carrying an activating EGFR mutation. 1st and 2nd generation agents lead to response rates of up to 70% in metastatic EGFRM+ NSCLC. Recently, new focus has been shed on intercalated regimens of chemotherapy and TKI showing improved PFS as well as OS in the metastatic setting in an unselected Asian population (Wu et al. 2013). Re…
Zitieren
Zitierempfehlung
F Griesinger, M Sebastian, M Serke, C Grohé, L Hillejan, B Passlick, N Reinmuth, U Graeven, S Radke, A Karatas, M Tiemann, T Overbeck (2016) Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: NeoIntercal. Pneumologie (02). https://doi.org/10.1055/s-0036-1572237
Mit CareLit weiterarbeiten